Noticias de KOD
Noticias del mercado
Últimas noticias sobre KOD — 235 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
Kodiak Sciences stock has a fresh Phase 3 catalyst after Zenkuda and KSI-501 met DAYBREAK endpoints
Las compras del 28 y 29 de septiembre de 2026 fueron indirectas. No se informó ningún plan de la Regla 10b5-1; el asesor tenía total autoridad para invertir y votar.
Weighted-average prices ranged from $61.2104 to $78.5681 per share for September 28, 2026 purchases. No Rule 10b5-1 plan is reported.
Each reporting person lists 22,049,297 shares; the ownership calculation includes 188,356 vested options held by board member Felix J. Baker.
Moderna, uniQure, Amgen, Iovance Biotherapeutics, Summit Therapeutics, Natera, and Kodiak Sciences are the seven Biotech stocks to watch today, according to MarketBeat
Kodiak Sciences (Nasdaq: KOD) closed up 177.96% at $89.92 as Phase 3 DAYBREAK met primary endpoints for Zenkuda and tabirafusp-ted in wet AMD.
Kodiak surges 178% as positive phase III DAYBREAK data show Zenkuda and tabirafusp-ted met key endpoints against Eylea.
Página 6 de 12